The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need. The clinical site is led by Brigham and Women’s Hospital researchers Ann Woolley, M.D., and David Leaf, M.D. The double-blind, placebo-controlled trial will examine outcomes for hospitalized patients with severe babesiosis, a tick-borne illness often found as a co-infection of Lyme disease.... Read More

Q3 2024 sales revenue increased 164% year-over-year to $135 thousand. Sequential (quarter-over-quarter) net product revenue growth of 8.3%. Gross profit increased from ($20 thousand) to $24 thousand. WASHINGTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their... Read More

Highlights include increased ARAKODA ® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade and is differentiated by a broad efficacy against all malaria stages, a convenient weekly dosing schedule, and a well-established safety profile.... Read More

WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced private placement, priced at-the-market under Nasdaq rules, of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu... Read More

WASHINGTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,898,551 shares of its common stock (or common stock equivalents in lieu thereof), series A warrants to... Read More

WASHINGTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on August 26, 2024 it received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has regained compliance with the minimum... Read More

Q2 2024 net product revenues doubled year-over-year to $125 thousand Sequential (quarter-over-quarter) net product revenue growth of 18.3% Gross profit increased from ($124 thousand) to $35 thousand, year-over-year WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported... Read More

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of reference allows FDA to review 60 Degrees Pharma’s regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program. WASHINGTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- 60... Read More

WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split (“Reverse Stock Split”) of its common stock, par value $0.0001 per share (“Common Stock”). The Common Stock will continue to trade on The Nasdaq Capital... Read More

60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development Activity to facilitate commercial validation of new bottle and replacement blister packaging of ARAKODA ® (tafenoquine), the Company’s FDA-approved product indicated for malaria prevention Anticipating increasing ARAKODA sales volume in 2024, the Company increased the commercial batch size of ARAKODA in Q1 2024 Q1... Read More

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University, Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025 In the Northeast U.S., the incidence of babesiosis has been increasing; babesiosis is an emerging, tick-borne, potentially life-threatening illness Case studies in recent medical literature suggest that... Read More

WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label, expanded access study of the ARAKODA ® regimen of tafenoquine in combination with standard of care regimens in immunosuppressed patients with... Read More

The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at Tufts Medical Center in Boston. Endpoints are time to sustained clinical resolution of symptoms of babesiosis, and molecular cure as determined by an FDA-approved nucleic acid test (NAT). Study is the world’s first and only clinical trial evaluating tafenoquine in human... Read More

With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees. 60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine... Read More

60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humans The study will be the world’s first clinical trial to evaluate tafenoquine in human babesiosis patients Enrollment will begin after a site initiation visit in Boston on June 13, 2024 Agreements are being negotiated with... Read More

Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infections Prominent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptoms Planned study at North Carolina State College of Veterinary Medicine will assess whether Babesia spp parasites are present in samples from patients with chronic... Read More

Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand. Gross profit increased from ($55.9 thousand) to $51.0 thousand. WASHINGTON, May 15, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2024... Read More

The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness. The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study to date. Enrollment is planned to begin in summer 2024. The Journal of Infectious Diseases has published a letter outlining the planned trial protocol.... Read More

Trial planning and execution to proceed as planned WASHINGTON, May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S. Food and Drug Administration (FDA) has provided comments on the protocol of a planned clinical trial that will study the use of tafenoquine in... Read More

Study to be conducted by North Carolina State University in 2024 Standard of care fails in 20 percent of cases and drug resistance is a problem Standard of care is expensive WASHINGTON, April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the Company will sponsor... Read More

WASHINGTON, March 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. , (NASDAQ: SXTP, SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has communicated its intention to send any comments regarding the Company’s babesiosis trial within the month of April,... Read More

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals Tafenoquine’s presumed mode of action against C. auris is differentiated from standard of care treatment Monash University will conduct the studies beginning in second quarter of 2024 WASHINGTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (the “Company,” “60P” or “60 Degrees Pharmaceuticals”) (NASDAQ:... Read More

To lead U.S. commercial relaunch of ARAKODA® (tafenoquine) for malaria prevention Will support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has... Read More

WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. ( NASDAQ: SXTP; SXTPW ) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its public offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre-funded units (the... Read More

JERSEY CITY, N.J. , Jan. 30, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc. ("60P"), (NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its public offering of 5,260,901 units (the "Units") at a price to the public of... Read More

WASHINGTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. ( NASDAQ: SXTP; SXTPW ) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the pricing of its public offering of 5,260,901 units (the “Units”) at a price to the public of $0.385 per Unit and 999,076 pre-funded units (the... Read More

Following a Type C meeting with FDA on January 17, 2024, 60 Degrees Pharma (60P) now plans to conduct a pivotal clinical study in support of a future indication for tafenoquine for treatment of hospitalized babesiosis patients Patient enrollment to begin in summer of 2024 WASHINGTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company... Read More

WASHINGTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating the Company has regained compliance with the minimum... Read More

Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis patients The previously announced Type C meeting with FDA has been rescheduled by FDA from January 15 to January 17, 2024, due to a federal holiday WASHINGTON, Dec. 26, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:... Read More

Type C meeting will be to discuss a proposed Phase II study of tafenoquine for treatment of babesiosis Transmitted by ticks, babesiosis is a life-threatening parasitic disease increasing in frequency in the United States Meeting with FDA scheduled for January 15, 2024 WASHINGTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused... Read More

60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting 60 Degrees Pharmaceuticals will also present a comprehensive review of the scientific literature on the use of 8-aminoquinolines in treating malaria and babesiosis in a sponsored symposium at ILADS, 2023 WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE)... Read More

FDA advice to Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S. Company will therefore focus efforts on further commercialization related to ARAKODA ® (tafenoquine) for prophylaxis of malaria, and prepare for a Phase IIA study of... Read More

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19; Company plans to resubmit a revised IND later in 2023, pending a feasibility assessment 60P has paused further study start-up preparations related to ACLR8-LR, decreasing the Company’s... Read More

Management investor presentation webcast available Monday 9/11, 7:00 AM ET Attendees may request 1 x 1 meetings with management at meetings@hcwco.com WASHINGTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP ), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that CEO Dr. Geoff Dow and CFO Ty Miller will... Read More

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp. Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market Presumed mode of action differentiated from standard of care treatment WASHINGTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (“60P”) (NASDAQ: SXTP), specialists in developing and marketing medicines for infectious... Read More

60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individuals Tafenoquine kills dormant liver stage of P. vivax parasite and clears the blood stages of P. falciparum WASHINGTON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals (“60P”) (Nasdaq: SXTP), specialists in developing and... Read More